COVID-19 redux: clinical, virologic, and immunologic evaluation of clinical rebound after nirmatrelvir/ritonavir.
Epling BP, Rocco JM, Boswell KL, Laidlaw E, Galindo F, Kellogg A, Das S, Roder A, Ghedin E, Kreitman A, Dewar RL, Kelly SEM, Kalish H, Rehman T, Highbarger J, Rupert A, Kocher G, Holbrook MR, Lisco A, Manion M, Koup RA, Sereti I.
Epling BP, et al.
medRxiv [Preprint]. 2022 Jun 17:2022.06.16.22276392. doi: 10.1101/2022.06.16.22276392.
medRxiv. 2022.
PMID: 35734093
Free PMC article.
Updated.
Preprint.